We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · June 20, 2020

Intrathecal Administration of Recombinant Human Hepatocyte Growth Factor in Patients With Acute Spinal Cord Injury

Journal of neurotrauma

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of neurotrauma
Phase I/II Study of Intrathecal Administration of Recombinant Human Hepatocyte Growth Factor in Patients With Acute Spinal Cord Injury: A Double-Blind, Randomized Clinical Trial of Safety and Efficacy
J. Neurotrauma 2020 May 22;[EPub Ahead of Print], N Nagoshi, O Tsuji, K Kitamura, K Suda, T Maeda, Y Yato, T Abe, D Hayata, M Matsumoto, H Okano, M Nakamura

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading